Systemic scleroderma—also known as systemic sclerosis (SS c)—is a chronic systemic
connective tissue disease characterized by collagen deposition in cutaneous and internal …

Background. The cutaneous changes seen in systemic sclerosis (SSc) can result in
considerable patient morbidity. Aim. We previously reported on the beneficial effect of …

Summary Background/Purpose Ultraviolet A1 (UVA 1) phototherapy has been used for over
15 years in the United States, primarily for the treatment of localized sclerosis and various …

Systemic and localized scleroderma are difficult to manage diseases with no accepted gold
standard of therapy to date. Phototherapeutic modalities for scleroderma show promise. A …

Purpose: To evaluate the efficacy of medium-dose UVA1 phototherapy in patients with
localized scleroderma. Method: A controlled pilot study with medium-dose UVA1 (48 J/cm2) …

Background: Numerous treatment modalities, some with potentially hazardous side effects,
are currently used for morphea (M) and systemic sclerosis (SS) with limited success. Low …

BACKGROUND: In previous trials, UV therapy has been demonstrated to be effective in the
treatment of localized scleroderma (LS). To date, a randomized comparison study to …

Background: UVA1 radiation seems to be effective in morphea. CD34+ dendritic cells are
significantly decreased in lesional skin of morphea patients. Objective: We evaluated the …

In systemic sclerosis (SSc; scleroderma) fibrosis of the skin can lead to considerable
morbidity. No significant improvement has been reported from studies investigating …

Sclerosing skin diseases such as localized scleroderma or lichen sclerosus frequently result
in significant morbidity that requires treatment. Until 10 years ago, no generally effective …